What is Phenomics?

How do you go from DNA to a person?

Thanks to advances in DNA and genome sequencing technology, there has been a rise in the number of sequenced genomes available for researchers. This includes human DNA that was sequenced and stored during the Human Genome Project.

It was hoped that the Human Genome Project would give new insight into diseases, and that it would also allow treatments to be personalized to individuals depending on their genetics. While Genome-Wide Association Studies (GWAS) have yielded new understandings of diseases such as schizophrenia and bipolar disorder, this has proved more difficult than originally imagined.

As genome sequencing becomes cheaper, the difficulty in interpreting the DNA sequence and how this influences the characteristics of an organism, known as the phenotype, has become the major hurdle. This has brought about the field of “phenomics”. This involves using bioimaging, biochemical and molecular analyses, and, in the case of diseases, clinical information, in order to determine the link between the DNA sequence and a specific phenotype.

Phenomics is the organism scale study of genotype-phenotype relationships.Image Credit: nobeastsofierce/Shutterstock.com

Phenomics case study

Phenotypes arise from the interaction between genes within a genome, and the environment. This is a highly complex interaction: for studying the phenomics of neuropsychiatric illnesses, this includes studying how the neural and cognitive systems work, and then trying to decipher how the genome links to these differences in the phenotype.

There is an additional challenge in using phenomics to study neuropsychiatric illnesses: the link between brain function and human behavior is complex, and not well understood. Thus, while organs such as the heart have been modeled from the genetic level to the whole organ, this is not possible for the brain.

Also, while certain phenotypes may be enough to characterize a neuropsychiatric illness, this does not necessarily mean that these phenotypes will be driven by genomic variations alone. There is a hypothesis known as “generalist gene hypothesis”, which is based on findings that suggest that a set of genes are linked to the majority of cognitive functions, such as intelligence and memory. This set of genes may involve hundreds of genes, and this high genetic correlation may be found in some neuropsychiatric illnesses too.

Bilder et al., proposed a scheme for neuropsychiatric phenomics studies, formed of levels, as follows:

  • genome
  • proteome
  • cellular system (signaling pathways)
  • neural systems
  • cognitive phenotype
  • symptoms
  • syndrome

This is a simplified approach, and each stage represents the key questions that should be asked in order to understand how the genes influence neuropsychiatric illnesses. The first three fall into the “central dogma of biology”, and this also forms part of other phenomics studies.

From there, this above scheme delves into ideas more specific to neuospychiatry. For example, how cells form neural systems, and in turn how this then influences cognitive functions such as mood, linguistic skills and thinking. This in turn forms the basis of symptoms, which may indicate a specific neuropsychiatric illness.  

Even though this scheme is simplified, it can be used to roughly calculate how small or large the phenomic search space is. Assuming that there are only seven changes that need to occur for a given genomic variant to result in disease, if a genomic variant influences five proteins, a protein influences five cellular systems, etc., there would be 15,625 such influences once the syndrome level is reached.

Conversely, if a neuropsychiatric illness may be identified by a collection of symptoms then one can imagine that there could be hundreds to thousands of genetic variations which had contributed to this illness. Thus, it can be seen that phenomics studies are highly complex, and need to account for a vast number of phenotypes or genomic variations.

Further Reading

Last Updated: Feb 1, 2021

Dr. Maho Yokoyama

Written by

Dr. Maho Yokoyama

Dr. Maho Yokoyama is a researcher and science writer. She was awarded her Ph.D. from the University of Bath, UK, following a thesis in the field of Microbiology, where she applied functional genomics to Staphylococcus aureus . During her doctoral studies, Maho collaborated with other academics on several papers and even published some of her own work in peer-reviewed scientific journals. She also presented her work at academic conferences around the world.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Yokoyama, Maho. (2021, February 01). What is Phenomics?. AZoLifeSciences. Retrieved on April 17, 2024 from https://www.azolifesciences.com/article/What-is-Phenomics.aspx.

  • MLA

    Yokoyama, Maho. "What is Phenomics?". AZoLifeSciences. 17 April 2024. <https://www.azolifesciences.com/article/What-is-Phenomics.aspx>.

  • Chicago

    Yokoyama, Maho. "What is Phenomics?". AZoLifeSciences. https://www.azolifesciences.com/article/What-is-Phenomics.aspx. (accessed April 17, 2024).

  • Harvard

    Yokoyama, Maho. 2021. What is Phenomics?. AZoLifeSciences, viewed 17 April 2024, https://www.azolifesciences.com/article/What-is-Phenomics.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Different Chromosomes Found to Have Separate End-Specific Telomere-Length Distributions